Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 252-256, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anker, G. B.
Right arrow Articles by Lønning, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anker, G. B.
Right arrow Articles by Lønning, P. E.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:252-256.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients

Gun B. Anker1, Helga Refsum2, Per M. Ueland2, Dag C. Johannessen1, Ernst A. Lien2 and Per E. Lønning1,a

Departments of
1 Oncology and
2 Pharmacology, Haukeland University Hospital, N-5021 Bergen, Norway.
a Author for correspondence. Fax 47-55-972046; e-mail Per.Lonning{at}onko.haukeland.no.

In this study, we evaluated the effect of estrogen suppression with three aromatase inhibitors, aminoglutethimide (n = 30), formestane (n = 12), and exemestane (n = 10), and the progestin megestrol acetate (n = 21) on plasma total homocysteine (tHcy) in patients suffering from advanced breast cancer. Treatment with 1 g/day aminoglutethimide for 2 and 3–5 months increased plasma tHcy by a mean value of 24.5% [95% confidence interval, 10.5–40.4%] at 2 months and 35.8% (95% confidence interval, 18.2–55.9%) at 3–5 months, corresponding to increases in the mean plasma tHcy of 1.90 and 3.67 µmol/L, respectively. In contrast, none of the other treatment options influenced plasma tHcy concentrations. The finding that aminoglutethimide, but none of the other aromatase inhibitors or megestrol acetate, influenced plasma tHcy suggests that this effect is achieved by mechanisms not related to suppression of plasma estrogens or to the glucocorticoids administered in concert.




The following articles in journals at HighWire Press have cited this article:


Home page
 Anticancer ResHome page
B. MELICHAR, H. KALABOVA, L. KRCMOVA, L. URBANEK, R. HYSPLER, D. SOLICHOVA, K. MELICHAROVA, M. PECKA, and Z. ZADAK
Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma
Anticancer Res, August 1, 2009; 29(8): 3337 - 3346.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. E. Lonning, J. Geisler, L. E. Krag, B. Erikstein, Y. Bremnes, A. I. Hagen, E. Schlichting, E. A. Lien, E. S. Ofjord, J. Paolini, et al.
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 5126 - 5137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al.
Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion
Clin. Chem., January 1, 2004; 50(1): 3 - 32.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.